Edenius holds a medical degree and has a PhD from the Karolinska Institute. She joined Medivir this month from Swedish pharmaceutical company Orexo, where she was senior vice president and chief scientific officer.
Prior to this, Edenius was vice president and chief scientific officer of Biolipox from 2001–2007 and held various executive positions in experimental medicine, Clinical R&D at AstraZeneca in Sweden.
Medivir’s key pipeline asset, TMC435, a protease inhibitor, is in phase 2b clinical development for Hepatitis C and is partnered with Tibotec Pharmaceuticals.
Medivir appoints vp for r&d projects
Charlotte Edenius takes up newly created position
You may also like
Regulatory
FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment
The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone
Research & Development
Scientists develop new technique to fight antimicrobial resistance
The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections
Research & Development
Lancet Oncology Commission launches to examine future of academic cancer clinical trials amid funding and regulatory pressures
A global coalition of clinical investigators and patient representatives has launched the Lancet Oncology Commission to address the value and challenges of independent academic cancer clinical trials, amid growing concerns over regulatory complexity, limited public funding and the need for new international collaboration models